Stock Short Interest Filing: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shorted Shares Increased By 1%

November 21, 2016 - By Dolores Ford   ·   0 Comments

Stock Short Interest Filing: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shorted Shares Increased By 1%

The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) registered an increase of 1% in short interest. VRTX’s total short interest was 5.62 million shares in November as published by FINRA. Its up 1% from 5.56M shares, reported previously. With 1.56M shares average volume, it will take short sellers 4 days to cover their VRTX’s short positions. The short interest to Vertex Pharmaceuticals Incorporated’s float is 2.42%. The stock decreased 1.93% or $1.76 on November 18, hitting $89.44. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 7.49% since April 19, 2016 and is uptrending. It has outperformed by 3.63% the S&P500.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has a market cap of $21.93 billion. The Firm operates in pharmaceuticals segment. It currently has negative earnings. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications.

Insitutional Activity: The institutional sentiment decreased to 1.1 in 2016 Q2. Its down 0.04, from 1.14 in 2016Q1. The ratio fall, as 53 funds sold all Vertex Pharmaceuticals Incorporated shares owned while 139 reduced positions. 43 funds bought stakes while 176 increased positions. They now own 236.53 million shares or 0.67% less from 238.13 million shares in 2016Q1.
Meiji Yasuda Asset Mngmt Com holds 0.03% or 2,339 shares in its portfolio. Reliance Com Of Delaware has 0.06% invested in the company for 9,489 shares. Bnp Paribas Arbitrage Sa has 150,862 shares for 0.06% of their US portfolio. Glenmede Na holds 0% or 700 shares in its portfolio. Putnam Limited Liability accumulated 0.11% or 545,176 shares. Moreover, Eventide Asset Management Limited Liability Corporation has 0.18% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 34,600 shares. The Japan-based Blackrock Japan Company Ltd has invested 0.1% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Federated Invsts Inc Pa has invested 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tocqueville Asset Mgmt Limited Partnership has 57,031 shares for 0.06% of their US portfolio. Andra Ap holds 0.03% or 12,600 shares in its portfolio. Regions Finance Corporation reported 122,184 shares or 0.14% of all its holdings. Moreover, Hirtle Callaghan And Com Limited Com has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 218 shares. Moreover, Tfs Cap has 0.06% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 4,018 shares. Alexandria Capital Lc holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 40 shares. California Employees Retirement Sys accumulated 522,100 shares or 0.07% of the stock.

Insider Transactions: Since May 25, 2016, the stock had 0 insider purchases, and 29 selling transactions for $17.66 million net activity. $591,372 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by BOGER JOSHUA S. The insider Silva Paul M sold $460,556. 1,208 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $108,720 were sold by Arbuckle Stuart A. $10,830 worth of shares were sold by Sachdev Amit on Tuesday, November 15.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Out of 16 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. Vertex Pharmaceuticals has been the topic of 30 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Nomura given on Wednesday, September 16. The firm has “Buy” rating given on Friday, October 30 by H.C. Wainwright. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Neutral” rating given on Thursday, April 28 by Goldman Sachs. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Outperform” rating given on Thursday, April 28 by RBC Capital Markets. The rating was maintained by Argus Research with “Buy” on Thursday, February 4. BMO Capital Markets initiated the shares of VRTX in a report on Thursday, April 7 with “Market Perform” rating. As per Thursday, September 29, the company rating was maintained by Jefferies. Stifel Nicolaus maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, September 15. Stifel Nicolaus has “Buy” rating and $109 price target. The firm earned “Outperform” rating on Wednesday, January 20 by Credit Suisse. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by Leerink Swann on Friday, February 5.

VRTX Company Profile

Vertex Pharmaceuticals Incorporated (Vertex), incorporated on January 4, 1989, is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Firm operates in pharmaceuticals segment. The Company’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Vertex’s two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. The Company’s VX-661 is a corrector compound that the Company is evaluating a Phase III development program in combination with ivacaftor in multiple CF patient populations having approximately one copy of the F508del mutation in their CFTR gene. The Company’s VX-371 is an investigational epithelial sodium channel (ENaC) inhibitor that is being evaluated in a Phase II development program. The Company’s VX-152 and VX-440 are two next-generation CFTR corrector compounds that entered Phase I clinical trials.

More news for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were recently published by: Fool.com, which released: “Vertex Pharmaceuticals Incorporated Pushes Forward With Drug Combinations (and …” on October 27, 2016. Nasdaq.com‘s article titled: “Earnings Reaction History: Vertex Pharmaceuticals Incorporated, 55.6% Follow …” and published on October 25, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>